Revenue ($USD) : $410,921,000
R&D spend : $46,610,000.00
Employees : 1,793
Fiscal year end : 12/31/22
CEO : Quentin Blackford

Wearable cardiac monitor maker iRhythm’s sales jumped more than 21% in the first half of 2023. The company reported its second-highest quarter for its Zio XT monitors, plus growth for its Zio AT device.

CEO Quentin Blackford said iRhythm will “continue to redefine the standard of cardiac care and demonstrate our unique value proposition to customers, patients, and payers.”

iRhythm has also faced challenges. In May, it received an FDA warning letter involving the Zio AT. The same month, it disclosed its third subpoena from federal investigators; company officials say they’re cooperating. –CN